Updated NETs Clinical Trials

1. Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors

   Conditions: Neuroendocrine Tumors Interventions: Diagnostic Test: Al18F-NOTA-LM3; Diagnostic Test: 68Ga-DOTATATE; Diagnostic Test: Al18F-NOTA-LM3; Diagnostic Test: 68Ga-NODAGA-LM3 Sponsors: Peking Union Medical College Hospital Recruiting

2. Perioperative Adiponectin and Postoperative Inflammatory Response After Major Abdominal Surgery

   Conditions: Obesity, Abdominal; Surgery; Systemic Inflammatory Response Syndrome; Postoperative Complications Interventions: Diagnostic Test: serum levels of adiponectin; Diagnostic Test: IL-6; Other: Postoperative systemic infflamation; Other: Postoperative complications Sponsors: Osijek University Hospital Recruiting

3. INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) for the Treatment of Advanced or Metastatic PD-(L)1 Refractory Merkle Cell Carcinoma

   Conditions: Clinical Stage III Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Merkel Cell Carcinoma AJCC v8; Merkel Cell Carcinoma Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Biological: Retifanlimab; Drug: Tuparstobart; Drug: Verzistobart Sponsors: University of Washington; Incyte Corporation Not yet recruiting

4. A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

   Conditions: Neuroendocrine Tumor (NET); Colorectal Cancer (CRC) Interventions: Biological: CHM-2101 CAR-T cells; Biological: CHM-2101 CAR-T cells Sponsors: Chimeric Therapeutics Not yet recruiting

5. Atezolizumab in Large Cell Neuroendocrine Carcinoma

   Conditions: Large Cell Neuroendocrine Carcinoma of the Lung Interventions: Drug: Atezolizumab; Drug: Carboplatin; Drug: Etoposide Sponsors: Oncology Center of Biochemical Education And Research Completed

6. Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy

   Conditions: Adrenal Tumor; Adrenal Disease; Adrenal Mass; Adrenalectomy; Status; Adrenal Hyperplasia; Adrenal Gland Metastasis; Adrenal Cortex Diseases; Pheochromocytoma; Cushing Syndrome; Conn Adenoma; Adrenocortical Carcinoma; Adrenocortical Adenoma; Adrenocortical Tumor Sponsors: University Hospital Olomouc; University Hospital Ostrava; Tomas Bata Hospital, Czech Republic; General University Hospital, Prague; University Hospital Hradec Kralove Recruiting

7. "Receptor Radionuclide Therapy With 177Lu-DOTATOC

   Conditions: Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma Interventions: Drug: 177Lu-DOTATOC Sponsors: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori Not yet recruiting

8. Evaluation of the Quality of Life and Tolerance of Patients Treated With Vectorized Internal Radiotherapy (RIV) for a Neuro Endocrine Tumor (NET) in the Auvergne-Rhône-Alpes Region.

   Conditions: Metastatic Neuroendocrine Tumour Sponsors: Hospices Civils de Lyon Not yet recruiting

9. Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations

   Conditions: Pancreatic Ductal Adenocarcinoma; Pancreatic Diseases; Pancreatic Elastase 1; Pancreatic Neuroendocrine Tumor; Pancreatitis; Pancreatic Neoplasms Interventions: Diagnostic Test: Pancreatic elastase-1 in blood serum Sponsors: Qilu Hospital of Shandong University; First Affiliated Hospital, Sun Yat-Sen University; First Affiliated Hospital of Guangxi Medical University; Wuhan Union Hospital, China; LanZhou University Recruiting

10. Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

    Conditions: Neuroendocrine Carcinomas; Neuroendocrine Tumors; Carcinoma, Neuroendocrine; Carcinoma, Adrenocortical; Carcinoma, Adrenal Cortical Interventions: Drug: ADCT-701 Sponsors: National Cancer Institute (NCI) Not yet recruiting

11. Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns

    Conditions: Merkel Cell Carcinoma Sponsors: Power Life Sciences Inc. Not yet recruiting

12. An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

    Conditions: Neuroendocrine Tumors Interventions: Drug: Surufatinib Combined With Temozolomide and S-1 Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting

13. The Effects of Sufentanil-remimazolam vs. Remifentanil-remimazolam Total Intravenous Anesthesia on Postoperative Pain in Laparoscopic-assisted Gastrectomy

    Conditions: Pheochromocytoma Interventions: Drug: dexmedetomidine; Drug: 0.9% normal saline Sponsors: Yonsei University Completed

14. Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction

    Conditions: Pancreatic Tumor, Benign; Pancreatic Neuroendocrine Tumor; Solid Pseudopapillary Tumor of the Pancreas Interventions: Procedure: MPD Repair or Reconstruction Sponsors: Fudan University; The Third Affiliated Hospital of Soochow University; Tongji Hospital; Qilu Hospital of Shandong University; Chinese PLA General Hospital; The Affiliated Hospital of Xuzhou Medical University Not yet recruiting

15. A Study of CRD3874-SI in People With Sarcoma or Merkel Cell Cancer

    Conditions: Sarcoma; Merkel Cell Carcinoma Interventions: Drug: CRD3874 Sponsors: Memorial Sloan Kettering Cancer Center; Curadev Pharma Recruiting

16. Role Of Sensitivity to neuroEndocrine Systems in Social Decisions

    Conditions: Borderline Personality Disorder Interventions: Drug: Hydrocortisone; Dietary Supplement: Yohimbine; Drug: Placebo Sponsors: University of North Carolina, Chapel Hill Not yet recruiting

17. Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

    Conditions: Digestive System Neuroendocrine Tumor G1; Digestive System Neuroendocrine Tumor G2; Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Malignant Neoplasm in the Liver; Pancreatic Neuroendocrine Tumor G1; Pancreatic Neuroendocrine Tumor G2 Interventions: Procedure: Tumor Debulking; Drug: Lutetium Lu 177 Dotatate; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: Copper Cu 64 Dotatate; Procedure: Positron Emission Tomography Sponsors: Vanderbilt-Ingram Cancer Center Not yet recruiting

18. Clinical Evaluation of the Effect of Metformin in Sepsis

    Conditions: Sepsis Interventions: Drug: Metformin Sponsors: German University in Cairo Recruiting

19. At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

    Conditions: Advanced Malignant Solid Neoplasm; Anal Carcinoma; Biliary Tract Carcinoma; Bladder Carcinoma; Breast Carcinoma; Carcinoid Tumor; Cervical Carcinoma; Colorectal Carcinoma; Gastric Carcinoma; Glioblastoma; Head and Neck Carcinoma; HER2-Positive Breast Carcinoma; Lung Carcinoma; Lung Small Cell Carcinoma; Malignant Germ Cell Tumor; Neuroendocrine Carcinoma; Ovarian Carcinoma; Pancreatic Carcinoma; Prostate Small Cell Neuroendocrine Carcinoma Interventions: Procedure: Clinical Encounter; Other: Home Health Encounter; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: Mayo Clinic Recruiting

20. A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

    Conditions: Small Cell Lung Carcinoma (SCLC); Neuroendocrine Neoplasms Interventions: Drug: BI 764532; Drug: [89Zr]Zr-BI 764532 Sponsors: Boehringer Ingelheim Not yet recruiting

21. Head and Neck Paragangliomas: A 16-year Experience of a University Hospital in Turkey

    Conditions: Head and Neck Paraganglioma Sponsors: Pamukkale University Completed

22. Long-term Prognosis for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cm

    Conditions: Non Functioning Pancreatic Endocrine Tumor Interventions: Other: Histopathological review, long-term prognosis and quality of life follow-up Sponsors: Fudan University; The Third Affiliated Hospital of Soochow University; Qilu Hospital of Shandong University; First Affiliated Hospital Xi'an Jiaotong University; Southern Medical University, China Recruiting

23. DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

    Conditions: Small Cell Lung Carcinoma; Neuroendocrine Neoplasms Interventions: Drug: BI 764532 Sponsors: Boehringer Ingelheim Not yet recruiting

24. A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

    Conditions: Small Cell Lung Carcinoma (SCLC); Neuroendocrine Neoplasms Interventions: Drug: BI 764532; Drug: Ezabenlimab Sponsors: Boehringer Ingelheim Recruiting

25. LUTATHERA Injection General Use Result Survey

    Conditions: Somatostatin Receptor-positive Neuroendocrine Tumor Interventions: Other: LUTATHERA Sponsors: Novartis Pharmaceuticals Recruiting

26. Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

    Conditions: Metastatic Midgut Neuroendocrine Tumor; Metastatic Midgut Neuroendocrine Tumor G1; Metastatic Midgut Neuroendocrine Tumor G2; Unresectable Midgut Neuroendocrine Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Everolimus; Drug: Lutetium Lu 177 Dotatate; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: National Cancer Institute (NCI) Recruiting

27. Potential Benefits of the Somatic Psychoeducational Intervention

    Conditions: Work Related Stress Interventions: Behavioral: Somatic Psychoeducational Intervention Sponsors: University of Florida Recruiting

28. Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

    Conditions: Metastatic Neuroendocrine Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Lutetium Lu 177 Dotatate; Procedure: Magnetic Resonance Imaging; Drug: Triapine Sponsors: National Cancer Institute (NCI) Recruiting

29. Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

    Conditions: Prostate Adenocarcinoma With Neuroendocrine Differentiation; Prostate Neuroendocrine Carcinoma; Prostate Small Cell Neuroendocrine Carcinoma; Stage IV Prostate Cancer AJCC v8 Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Lutetium Lu 177 Dotatate; Procedure: Positron Emission Tomography Sponsors: National Cancer Institute (NCI) Recruiting

30. A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

    Conditions: Small Cell Lung Cancer; Neuroendocrine Carcinoma Interventions: Drug: RO7616789; Drug: Tocilizumab Sponsors: Hoffmann-La Roche Recruiting

31. A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

    Conditions: Pancreatic Ductal Adenocarcinoma (PDAC); Squamous Cell Carcinoma of Head and Neck; Colorectal Cancer; Gastric Cancer; Ewing Sarcoma; NTSR1 Expressing Solid Tumours; Neuroendocrine Differentiated (NED) Prostate Cancer Interventions: Drug: [225]-FPI-2059; Drug: [111In]-FPI-2058 Sponsors: Fusion Pharmaceuticals Inc. Recruiting

32. Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

    Conditions: Advanced Solid Tumors Interventions: Drug: ABBV-706; Drug: Cisplatin; Drug: Budigalimab; Drug: Carboplatin Sponsors: AbbVie Recruiting

33. PSMA in Gastrointestinal Tumors (GIPSMA, Focusing on Neuroendocrine Neoplasms)

    Conditions: Gastrointestinal Cancer Interventions: Radiation: 18F-PSMA PET/CT Sponsors: Wuerzburg University Hospital Recruiting

34. Study of Oral MRT-2359 in Selected Cancer Patients

    Conditions: NSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC With High or Low L-MYC or N-MYC Expression; SCLC With High or Low L-MYC or N-MYC Expression Interventions: Drug: Oral MRT-2359; Drug: Oral MRT-2359; Drug: Oral MRT-2359; Drug: Oral MRT-2359 Sponsors: Monte Rosa Therapeutics, Inc Recruiting

35. Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

    Conditions: GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET Interventions: Drug: RYZ101; Drug: Everolimus 10 mg; Drug: Sunitinib 37.5 MG; Drug: Octreotide LAR 60 MG Injection; Drug: Lanreotide 120Mg Sa Susp Inj Syringe Sponsors: RayzeBio, Inc. Recruiting

36. Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden Death

    Conditions: Primary Aldosteronism; Adrenal Cushing Syndrome; Pheochromocytoma; Endocrine Neoplasia Interventions: Diagnostic Test: Adrenal aldosterone synthase (CYP11B2) staining; Diagnostic Test: Adrenal cortisol synthase (CYP11B1) staining; Diagnostic Test: Histopathological analysis Sponsors: Helsinki University Central Hospital; Finnish Institute for Health and Welfare; University of Helsinki; Tampere University Hospital; Tampere University Recruiting

37. 68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET

    Conditions: Neuroendocrine Tumor Carcinoid; Neuroendocrine Tumor of Pancreas; Gep Net Sponsors: European Institute of Oncology Active, not recruiting

38. Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

    Conditions: Carcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum; Carcinoid Tumor of Cecum; Carcinoid Syndrome Diarrhea; Carcinoid Intestine Tumor; Carcinoid Tumor of Liver; Carcinoid Tumor of Pancreas Interventions: Drug: Randomized: 40 mg Paltusotine; Drug: Randomized: 80 mg Paltusotine Sponsors: Crinetics Pharmaceuticals Inc. Recruiting

39. A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

    Conditions: Microsatellite High Cancers; Peritoneal Mesothelioma; Extrapulmonary High Grade; Neuroendocrine Carcinomas; Cervical Carcinoma; Hodgkin's Lymphoma; Pleural Mesothelioma; Small Cell Lung Cancer Interventions: Drug: XmAb20717 Sponsors: M.D. Anderson Cancer Center Recruiting

40. Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

    Conditions: Atypical Teratoid/Rhabdoid Tumor; Epithelioid Sarcoma; Kidney Medullary Carcinoma; Malignant Solid Neoplasm; Poorly Differentiated Chordoma; Recurrent Atypical Teratoid/Rhabdoid Tumor; Recurrent Chordoma; Recurrent Epithelioid Sarcoma; Recurrent Kidney Medullary Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Rhabdoid Tumor; Refractory Atypical Teratoid/Rhabdoid Tumor; Refractory Chordoma; Refractory Epithelioid Sarcoma; Refractory Kidney Medullary Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Rhabdoid Tumor; Rhabdoid Tumor Interventions: Biological: Atezolizumab; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Other: Fludeoxyglucose F-18; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Biological: Tiragolumab; Procedure: X-Ray Imaging Sponsors: National Cancer Institute (NCI) Recruiting

41. Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

    Conditions: Metastatic Pancreatic Neuroendocrine Tumor; Unresectable Pancreatic Neuroendocrine Carcinoma Interventions: Drug: Lutetium Lu 177 Dotatate; Drug: Capecitabine; Drug: Temozolomide; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Recruiting

42. A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

    Conditions: Prostate Cancer; Breast Cancer; Neuroendocrine Tumors Interventions: Diagnostic Test: Total-body PET imaging Sponsors: University of California, Davis; Lantheus Medical Imaging Not yet recruiting

43. Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients >= 18 Years Old With Advanced Stage Rare Cancers, RARE 2 Study

    Conditions: Adrenal Gland Pheochromocytoma; Hematopoietic and Lymphoid System Neoplasm; Malignant Solid Neoplasm; Paraganglioma Interventions: Procedure: Computed Tomography; Drug: Talazoparib; Drug: Temozolomide Sponsors: National Cancer Institute (NCI) Recruiting

44. Evaluation of the CONVIVO System

    Conditions: Glioblastoma; Glial Tumor; Brain Metastases; Meningioma; Schwannoma; Pituitary Tumor Interventions: Diagnostic Test: CONVIVO system; Other: Conventional histologic evaluation Sponsors: Dartmouth-Hitchcock Medical Center; Carl Zeiss Meditec, Inc. Recruiting

45. Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma

    Conditions: Vestibular Schwannoma Interventions: Dietary Supplement: Omega-3; Dietary Supplement: Placebo Sponsors: Mayo Clinic Terminated

46. Hypofractionated Radiation Therapy for Merkel Cell Carcinoma

    Conditions: Merkel Cell Carcinoma Interventions: Drug: Radiation therapy Sponsors: M.D. Anderson Cancer Center Recruiting

47. Neuroendocrine Tumors - Patient Reported Outcomes

    Conditions: Neuroendocrine Tumors; Gastroenteropancreatic Neuroendocrine Tumor; Lung Neuroendocrine Neoplasm; Neuroendocrine Carcinoma Sponsors: University of Iowa; Allina Health System; Medical College of Wisconsin; University of Kansas Medical Center; University of Texas Southwestern Medical Center; University of Utah; University of Florida; Ohio State University; University of Michigan; University of Pittsburgh Medical Center; Medical University of South Carolina; University of North Carolina, Chapel Hill; Vanderbilt University Medical Center; Mayo Clinic; Northern California CarciNET Community; Neuroendocrine Cancer Awareness Network; Neuroendocrine Tumor Research Foundation; Healing NET Foundation; Patient-Centered Outcomes Research Institute Enrolling by invitation

48. Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

    Conditions: Carcinomas; Cervix Cancer; Cervical Cancer Interventions: Drug: AK104 Sponsors: M.D. Anderson Cancer Center Recruiting

49. Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

    Conditions: Advanced Extrapulmonary Neuroendocrine Carcinoma; Metastatic Extrapulmonary Neuroendocrine Carcinoma; Recurrent Extrapulmonary Neuroendocrine Carcinoma; Unresectable Extrapulmonary Neuroendocrine Carcinoma Interventions: Biological: Atezolizumab; Procedure: Biospecimen Collection; Drug: Carboplatin; Drug: Cisplatin; Procedure: Computed Tomography; Drug: Etoposide; Procedure: Magnetic Resonance Imaging; Other: Patient Observation Sponsors: National Cancer Institute (NCI) Recruiting

50. Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

    Conditions: Bile Duct Cancer; Gall Bladder Cancer; Breast Cancer; Neuroendocrine Tumors; Ovarian Cancer; Pancreatic Adenocarcinoma; Soft Tissue Sarcoma; Vulvar Cancer; Prostate Cancer Interventions: Drug: Atezolizumab; Drug: Tivozanib Sponsors: University of Florida; Genentech, Inc.; Aveo Oncology Pharmaceuticals Recruiting